Alzheimer's Disease Research

Alzheimer's disease (AD), the most common type of dementia, is an irreversible and progressive neurodegenerative disorder causing cognitive and functional impairment. It is characterized by formation of protein aggregates and progressive loss of neurons in the central nervous system (CNS). The symptoms of AD include short-term memory loss, confusion, irritability, aggression and mood swings, progressing to long-term memory deficit, withdrawal from social interactions and subsequently a loss in higher central functioning.

Alzheimer's Disease Research Products Targets

Products for Alzheimer's Disease Research - Page 34

Cat.No. Product Name Information/Activity
BCC6552 DL-AP5 76326-31-3
BCC6554 L-AP5 79055-67-7
BCC6551 DL-AP7 78966-69-5
BCC6631 Arcaine sulfate 14923-17-2
BCC6602 (R)-4-Carboxyphenylglycine 134052-68-9
BCC7078 CGP 37849 CGP 37849 is a potent, competitive and orally active N-methyl-D-aspartate (NMDA) receptor antagonist. CGP 37849 is an anticonvulsant in rodents and has antidepressant and anxiolytic-like effects.
BCC7053 CGP 39551 127910-32-1
BCC7087 CGP 78608 hydrochloride CGP 78608 hydrochloride is a highly potent and selective antagonist at the glycine-binding site of the NMDA receptor, with an IC50 of 6 nM. CGP 78608 acts as a potentiator of GluN1/GluN3A-mediated glycine currents, with an estimated EC50 in the low nM range (26.3 nM). Anticonvulsant activity.
BCC6986 CGS 19755 110347-85-8
BCC7757 7-Chlorokynurenic acid sodium salt 7-Chlorokynurenic acid sodium salt (7-CKA sodium salt) is a potent and selective antagonist of the glycine B coagonist site of the N-methyl-D-aspartate (NMDA) receptor (IC50=0.56 μM). 7-Chlorokynurenic acid sodium salt is also a potent inhibitor of the reuptake of glutamate into synaptic vesicles with a Ki of 0.59 μM. 7-Chlorokynurenic acid sodium salt has potent antinociceptive actions after neuraxial delivery.